12/3
11:43 am
xers
What Analysts Think Is Changing The Story For Xeris Biopharma Holdings [Yahoo! Finance]
Low
Report
What Analysts Think Is Changing The Story For Xeris Biopharma Holdings [Yahoo! Finance]
12/1
07:00 am
xers
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
Medium
Report
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
11/12
08:11 am
xers
Xeris Biopharma (NASDAQ:XERS) had its price target raised by analysts at Piper Sandler from $6.00 to $8.00. They now have a "neutral" rating on the stock.
Low
Report
Xeris Biopharma (NASDAQ:XERS) had its price target raised by analysts at Piper Sandler from $6.00 to $8.00. They now have a "neutral" rating on the stock.
11/12
08:11 am
xers
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
11/12
08:11 am
xers
Xeris Biopharma (NASDAQ:XERS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $18.00 price target on the stock.
Low
Report
Xeris Biopharma (NASDAQ:XERS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $18.00 price target on the stock.
11/9
07:03 pm
xers
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance]
Low
Report
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance]
11/6
09:50 am
xers
Xeris Biopharma (XERS) Q3 2025 Earnings Transcript [Yahoo! Finance]
Low
Report
Xeris Biopharma (XERS) Q3 2025 Earnings Transcript [Yahoo! Finance]
11/6
07:43 am
xers
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025 [Yahoo! Finance]
Low
Report
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025 [Yahoo! Finance]
11/6
07:00 am
xers
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
High
Report
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
11/1
06:55 am
xers
Xeris Biopharma (NASDAQ:XERS) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Xeris Biopharma (NASDAQ:XERS) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
10/29
10:07 am
xers
Xeris Biopharma (NASDAQ:XERS) was given a new $18.00 price target on by analysts at Oppenheimer Holdings, Inc..
Low
Report
Xeris Biopharma (NASDAQ:XERS) was given a new $18.00 price target on by analysts at Oppenheimer Holdings, Inc..
10/24
12:26 pm
xers
Xeris Biopharma (NASDAQ:XERS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Xeris Biopharma (NASDAQ:XERS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/23
07:30 am
xers
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
Low
Report
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
10/18
01:31 am
xers
Xeris Biopharma (NASDAQ:XERS) was upgraded by analysts at
Wall Street Ze
Low
Report
Xeris Biopharma (NASDAQ:XERS) was upgraded by analysts at
Wall Street Ze
10/15
07:12 am
xers
Xeris Biopharma (NASDAQ:XERS) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
High
Report
Xeris Biopharma (NASDAQ:XERS) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
10/13
09:59 am
xers
Beat the Market the Zacks Way: MariMed, Xeris Biopharma, Lam Research in Focus [Yahoo! Finance]
Low
Report
Beat the Market the Zacks Way: MariMed, Xeris Biopharma, Lam Research in Focus [Yahoo! Finance]
10/8
12:39 pm
xers
Xeris Biopharma (NASDAQ:XERS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Xeris Biopharma (NASDAQ:XERS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/3
04:15 pm
xers
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/3
03:48 pm
xers
Xeris Biopharma (NASDAQ:XERS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Xeris Biopharma (NASDAQ:XERS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/3
10:40 am
xers
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Are Analysts Optimistic? [Yahoo! Finance]
Low
Report
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Are Analysts Optimistic? [Yahoo! Finance]
9/6
12:32 am
xers
Xeris Biopharma (NASDAQ:XERS) was downgraded by analysts at
Wall Street
Low
Report
Xeris Biopharma (NASDAQ:XERS) was downgraded by analysts at
Wall Street
9/6
12:32 am
xers
Xeris Biopharma (NASDAQ:XERS) was downgraded by analysts at
Wall Street
Low
Report
Xeris Biopharma (NASDAQ:XERS) was downgraded by analysts at
Wall Street
9/5
10:05 am
xers
Xeris In Recorlev-Fuelled Growth: Why I Choose To Buy [Seeking Alpha]
Neutral
Report
Xeris In Recorlev-Fuelled Growth: Why I Choose To Buy [Seeking Alpha]